Searchable abstracts of presentations at key conferences in endocrinology

ea0081p535 | Adrenal and Cardiovascular Endocrinology | ECE2022

Minimally invasive treatment of conn’s adenoma: real world cases in tertiary oncology center

Costa Claudia , Franco Sara , Santos Ana Paula , Goncalves Belarmino , Gil-Santos Sara , Oliveira Joana , Souteiro Pedro , Jose Sousa Maria , Torres Isabel

Introduction: Primary aldosteronism (PA) is a rare but underestimated cause of hypertension. PA has been associated with increased risk of malignancy through mechanisms involving up-regulation of the renin angiotensin system (RAS) promoting an enzymatic cascade influencing carcinogenesis. Recently, Microwave Ablation (MWA) has been established as an effective and safe minimal invasive treatment for Conn’s Disease.Aim: The authors present four clinic...

ea0081p489 | Thyroid | ECE2022

cGMP is not involved in thyroid cancer cell death

D'Alessandro Sara , Paradiso Elia , Lazzaretti Clara , Sperduti Samantha , Baschieri Lara , Mascolo Elisa , Roy Neena , Anzivino Claudia , Righi Sara , Santi Daniele , Brigante Giulia , Simoni Manuela , Casarini Livio

Introduction: Type 5 phosphodiesterase (PDE5) inhibitors (PDE5i) lead to intracellular cyclic-guanosine monophosphate (cGMP) increase and are used for clinical treatment of erectile dysfunction. Studies found that cGMP may up/downregulate the growth of certain endocrine tumor cells, suggesting that the use of PDE5i could impact the risk of certain tumors, such as colorectal cancer.Aim: We evaluated if PDE5i may impact thyroid cancer cell growth in vi...

ea0090p388 | Endocrine-related Cancer | ECE2023

PRRT 177Lu-DOTA-TATE in pancreatic neuroendocrine tumors – When to initiate?

Franco Sara , Lucena Sampaio Ines , Ferreira Goncalo , Barbosa Daniel , Gil-Santos Sara , Vara Luiz Henrique , Paula Santos Ana , Torres Isabel , Duarte Hugo

Introduction: The best timing for PRRT (peptide receptor radionuclide therapy) in the case of pancreatic neuroendocrine tumors (panNETs) is still to define, as randomized prospective trials are lacking. Recent studies suggest that some systemic therapies can affect response to PRRT, favoring an earlier use of the latter.Objective: To determine the efficacy and toxicity of PRRT, comparing its results when used as a second line systemic therapy (a...

ea0037ep293 | Calcium and Vitamin D metabolism | ECE2015

An oral high dose of cholecalciferol restores vitamin D status in deficient postmenopausal HIV-1 infected women independently of protease inhibitors therapy

Pepe Jessica , Mezzaroma Ivano , Fantauzzi Alessandra , Falciano Mario , Salotti Alessandra , Di Traglia Mario , Diacinti Daniele , Belcastro Sara , Piemonte Sara , Cipriani Cristiana , Minisola Salvatore

Introduction: The best repletion and maintenance dosing regimens with cholecalciferol in vitamin D deficient HIV-1 patients remain unknown. Protease inhibitors (PIs) have been shown to inhibit vitamin D 1α- and 25α-hydroxylation in hepatocyte and monocyte cultures. We therefore evaluated the effect of a single high dose of cholecalciferol in vitamin D deficient HIV-1 postmenopausal women undergoing treatment with highly Active Anti-Retroviral Therapy (cART), with and...

ea0070aep620 | Pituitary and Neuroendocrinology | ECE2020

Growth hormone deficiency in childhood acute lymphoblastic leukemia survivors – should systematic stimulation test be performed in all irradiated children?

Damasio Ines , Cavaco Daniela , Maciel Joana , Dias Daniela , Donato Sara , Pinheiro Sara , Figueiredo Ana , Simões-Pereira Joana , Pereira Conceiçao

Introduction: The combination of chemotherapy with prophylatic cranial radiotherapy (C-RT) allowed the improvement of survival rates of pediatric acute lymphoblastic leukemia (ALL) survivors while putting them at risk of develeping long-term endocrine deficiencies, like growth hormone deficiency (GHD).Current evidence suggests that the prevalence of GHD in children treated with radiation doses ≥ 30–50 Gy for non-pituitary brain tumors is...

ea0099ep207 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Estimated glucose disposal rate as a predictor of chronic complications in type 1 diabetes – a cross-sectional study

Jesus Nuno , Tavares Patricia , Alexandrino Henrique , Silva Jose , Goncalves Margarida , Sousa Ana , Rocha Gustavo , Ferreira Marta , Correia Sara , Monteiro Sara , Oliveira Maria

Introduction: Insulin resistance, often implicated in the pathophysiology of Type 2 Diabetes Mellitus, can also occur in patients with Type 1 Diabetes Mellitus (T1DM), giving rise to a distinct phenotype that some authors describe as Double Diabetes - a population with a higher risk of developing chronic complications. The estimated glucose disposal rate (eGDR) is a validated marker of insulin resistance in Type 1 Diabetes (T1DM), based on data obtained from the hyperinsulinem...

ea0077oc5.4 | Bone and Calcium | SFEBES2021

Nuclear factor I/X (NFIX) regulates the transcriptional activity of the cellular retinoic acid binding protein 2 (CRABP2) promoter and alters CRABP2 expression in Marshall-Smith Syndrome (MSS) patients.

Kooblall Kreepa , Stevenson Mark , Lines Kate , Stewart Michelle , Wells Sara , Teboul Lydia , Hennekam Raoul , Thakker Rajesh

Marshall-Smith syndrome (MSS) is a congenital disorder affecting skeletal and neural development, due to mutations in the nuclear factor I/X (NFIX) gene. NFIX encodes a ubiquitously expressed transcription factor that regulates the expression of viral and cellular genes. To identify novel genes that are misregulated by NFIX mutations, RNA sequencing and proteomics analyses were performed on mouse embryonic fibroblast (MEF) cells derived from a repres...

ea0077p70 | Metabolism, Obesity and Diabetes | SFEBES2021

Real-world metabolic outcomes of semaglutide use in patients with type 2 diabetes: a retrospective study from a single centre in the United Arab Emirates

Allum Matthew , Buckley Adam , Lessan Nader , Mohammed Nagi , Suliman Mohamed , Suliman Sara , Elsheikh Mohgah

Background: The Glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide has shown improvements in glycaemia and other metabolic parameters for patients with type 2 diabetes (T2D) in clinical trials. Published real-world data are sparse and there are none from the Middle East where semaglutide became available in 2020.Method and Results: We retrospectively gathered data for 289 patients (median age 50 years (IQR 42-57), 36% female, 87% Emirati and 8...

ea0077p184 | Metabolism, Obesity and Diabetes | SFEBES2021

Does human serum impact differentiation and mitochondrial function of human LHCN-M2 skeletal muscle cells?

Turner Mark , Saini Amarjit , Brown Holly , Anisi Sara , Stewart Claire , Renshaw Derek

Introduction: Skeletal muscle cells enable investigation of myogenesis and metabolic function in vitro. Exposure to human serum can provide insight into the impact of endocrine factors upon differentiation and mitochondrial function of skeletal muscle. The aim of these experiments was to optimise the culture conditions using human serum, which it was hypothesised would enhance myogenesis and mitochondrial function of LHCN-M2 human skeletal muscle cells.<p class="a...

ea0081rc14.7 | Rapid Communications 14: Late Breaking | ECE2022

Prognostic value of contralateral suppression on eGFR after surgery in primary aldosteronism

Krogh Jesper , Voss Nathalie , Larsen Feltoft Claus , Morup Sara , Clausen Caroline , Andreassen Mikkel

Adrenalectomy for primary aldosteronism has been associated with post-surgical kidney failure. It has been proposed that elimination of excess aldosterone demask an underlying failure of the kidney function. Contralateral suppression (CLS) is considered an indication of aldosterone excess and disease severity and the purpose of this study was to assess the hypothesis that CLS would predict change in kidney function after adrenalectomy in patients with primary aldosteronism. We...